Beneficial effects of treatment with transglutaminase inhibitor cystamine on the severity of inflammation in a rat model of inflammatory bowel disease

Laboratory Investigation

Volumn 91, Issue 3, 2011, Pages 452-461

  Elli, Luca ^a   Ciulla, Michele M ^b   Busca, Giuseppe ^b   Roncoroni, Leda ^b   Maioli, Claudio ^b   Ferrero, Stefano ^b   Bardella, Maria Teresa ^a,b   Bonura, Antonella ^b   Paliotti, Roberta ^b   Terrani, Claudia ^a   Braidotti, Paola ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

colitis; cystamine; inflammatory bowel disease; transglutaminase type 2

Indexed keywords

CYSTAMINE; INTERLEUKIN 6; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; ENTERITIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLON; CYSTAMINE; ENZYME INHIBITORS; FEMALE; GTP-BINDING PROTEINS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; TRANSGLUTAMINASES; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952078818     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.186     Document Type: Article

References (45)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347: 417-429. (Pubitemid 34851835)
2. Yamamoto-Furusho JK, Podolsky DK. Innate immunity in inflammatory bowel disease. World J Gastroenterol 2007;13:5577-5580. (Pubitemid 350031477)
3. Tsianos EV, Katsanos K. Do we really understand what the immunological disturbances in inflammatory bowel disease mean? World J Gastroenterol 2009;15:521-525.
4. Domenech E. Inflammatory bowel disease: current therapeutic options. Digestion 2006;73(Suppl 1):67-76.
5. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-1197.
6. Noble A, Baldassano R, Mamula P. Novel therapeutic options in the inflammatory bowel disease world. Dig Liver Dis 2008;40:22-31. (Pubitemid 350246390)
7. Lesort M, Lee M, Tucholski J, et al. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003;278:3825-3830. (Pubitemid 36801110)
8. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 2007;115:232-245. (Pubitemid 47042912)
9. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J 2002;368(Pt 2):377-396. (Pubitemid 35454517)
10. Elli L, Bergamini CM, Bardella MT, et al. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis 2009;41:541-550.
11. Jeitner TM, Pinto JT, Krasnikov BF, et al. Transglutaminases and neurodegeneration. J Neurochem 2009;109(Suppl 1):160-166.
12. Van Raamsdonk JM, Pearson J, Bailey CD, et al. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 2005;95:210-220. (Pubitemid 41384439)
13. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002;27:534-539. (Pubitemid 35279599)
14. Nardacci R, Ciccosanti F, Falasca L, et al. Tissue transglutaminase in HCV infection. Cell Death Differ 2003;10(Suppl 1):S79-S80.
15. Amendola A, Fesus L, Piacentini M, et al. 'Tissue' transglutaminase in AIDS. J Immunol Methods 2002;265:145-159.
16. Collighan RJ, Griffin M. Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids 2009;36:659-670.
17. D'Argenio G, Calvani M, Della Valle N, et al. Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis. Gut 2005;54:496-502. (Pubitemid 40395501)
18. Sjober K, Eriksson S, Tenngart B, et al. Factor XIII and tissue transglutaminase antibodies in coeliac and inflammatory bowel disease. Autoimmunity 2002;35:357-364. (Pubitemid 35189678)
19. Tursi A. Anti-tissue transglutaminase in inflammatory bowel diseases: an activity disease-related phenomenon? Dig Liver Dis 2006;38:711-712. (Pubitemid 44356263)
20. Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004;50:81-92. (Pubitemid 39286320)
21. Kankuri E, Vaali K, Korpela R, et al. Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflammation 2001;25:301-310. (Pubitemid 34093586)
22. San-Miguel B, Crespo I, Kretzmann NA, et al. Glutamine prevents fibrosis development in rats with colitis induced by 2,4,6- trinitrobenzene sulfonic acid. J Nutr 2010;140:1065-1071.
23. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol 2000;19:51-62. (Pubitemid 30146942)
24. Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803. (Pubitemid 19057602)
25. Gaudio E, Taddei G, Vetuschi A, et al. Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. Dig Dis Sci 1999;44:1458-1475. (Pubitemid 29404313)
26. Roncoroni L, Elli L, Dolfini E, et al. Resveratrol inhibits cell growth in a human cholangiocarcinoma cell line. Liver Int 2008;28:1426-1436.
27. Herman JP, Morrison DG. Immunoautoradiographic and in situ hybridization analysis of corticotropin-releasing hormone biosynthesis in the hypothalamic paraventricular nucleus. J Chem Neuroanat 1996;11:49-56. (Pubitemid 26248751)
28. Toohey JI. Sulfur metabolism in AIDS: cystamine as an anti-HIV agent. AIDS Res Hum Retroviruses 2009;25:1057-1060.
29. Jokay I, Kelemenics K, Gyuris A, et al. S-methylthio-cysteine and cystamine are potent stimulators of thiol production and glutathione synthesis. Life Sci 1998;62:PL27-PL33. (Pubitemid 28026752)
30. Kovarova H, Pulpanova J. Effect of cystamine on rat tissue GSH level and glutathione reductase activity. Strahlentherapie 1979;155: 875-878. (Pubitemid 10181195)
31. Jeitner TM, Delikatny EJ, Ahlqvist J, et al. Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem Pharmacol 2005;69: 961-970. (Pubitemid 40312713)
32. Beninati S, Bergamini CM, Piacentini M. An overview of the first 50 years of transglutaminase research. Amino Acids 2009;36:591-598.
33. Schuppan D, Dieterich W. A molecular warhead and its target: tissue transglutaminase and Celiac Sprue. Chem Biol 2003;10:199-201. (Pubitemid 36380273)
34. D'Argenio G, Biancone L, Cosenza V, et al. Transglutaminases in Crohn's disease. Gut 1995;37:690-695.
35. D'Argenio G, Cosenza V, Riegler G, et al. Serum transglutaminase correlates with endoscopic and histopathologic grading in patients with ulcerative colitis. Dig Dis Sci 2001;46:649-657. (Pubitemid 32299824)
36. Hudson M, Wakefield AJ, Hutton RA, et al. Factor XIIIA subunit and Crohn's disease. Gut 1993;34:75-79. (Pubitemid 23015954)
37. Kim SY. Transglutaminase 2 in inflammation. Front Biosci 2006;11: 3026-3035.
38. D'Argenio G, Grossman A, Cosenza V, et al. Recombinant factor XIII improves established experimental colitis in rats. Dig Dis Sci 2000;45:987-997. (Pubitemid 30238263)
39. Lorenz R, Born P, Classen M. [Substitution of factor XIII concentrate in treatment refractory ulcerative colitis. A prospective pilot study]. Med Klin (Munich) 1994;89:534-537. (Pubitemid 24330756)
40. Sohn J, Kim TI, Yoon YH, et al. Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J Clin Invest 2003; 111:121-128. (Pubitemid 36134855)
41. Falasca L, Farrace MG, Rinaldi A, et al. Transglutaminase type II is involved in the pathogenesis of endotoxic shock. J Immunol 2008;180:2616-2624.
42. Goldstone SD, Fragonas JC, Jeitner TM, et al. Transcription factors as targets for oxidative signalling during lymphocyte activation. Biochim Biophys Acta 1995;1263:114-122.
43. Mitsuyama K, Sata M, Rose-John S. Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev 2006;17: 451-461. (Pubitemid 44793118)
44. Mohan K, Pinto D, Issekutz TB. Identification of tissue transglutaminase as a novel molecule involved in human CD8+ T cell transendothelial migration. J Immunol 2003;171:3179-3186. (Pubitemid 37093543)
45. Bailey CD, Johnson GV. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiol Aging 2006;27:871-879. (Pubitemid 44287905)